Results summary | View all lists in GO:BiolProc | View all genes in R01AD.profile.ud50 |
The process whose specific outcome is the progression of the cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a specific fate. enrichment: 1.91-fold |
![]() |
![]() | |||||||||||
Probe ID | Name | G | T | D | X | E | P | R | C | S | ![]() |
![]() |
Description |
203140_AT | BCL6 | G | D | X | R | C | S | ![]() |
![]() |
B-cell CLL/lymphoma 6 (zinc finger protein 51) | |||
212501_AT | CEBPB | G | D | X | P | R | ![]() |
![]() |
CCAAT/enhancer binding protein (C/EBP), beta | ||||
217838_S_AT | EVL | T | D | X | P | S | ![]() |
![]() |
Enah/Vasp-like | ||||
203373_AT | SOCS2 | G | S | ![]() |
![]() |
suppressor of cytokine signaling 2 | |||||||
204999_S_AT | ATF5 | G | R | ![]() |
![]() |
activating transcription factor 5 | |||||||
204998_S_AT | ATF5 | G | R | ![]() |
![]() |
activating transcription factor 5 | |||||||
222152_AT | PDCD6 | G | ![]() |
![]() |
programmed cell death 6 | ||||||||
203685_AT | BCL2 | G | T | X | S | ![]() |
![]() |
B-cell CLL/lymphoma 2 | |||||
219209_AT | IFIH1 | G | X | ![]() |
![]() |
interferon induced with helicase C domain 1 | |||||||
209121_X_AT | NR2F2 | D | E | R | S | ![]() |
![]() |
nuclear receptor subfamily 2, group F, member 2 | |||||
205486_AT | TESK2 | G | P | C | S | ![]() |
![]() |
testis-specific kinase 2 | |||||
201502_S_AT | NFKBIA | G | T | D | S | ![]() |
![]() |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | |||||
201324_AT | EMP1 | G | D | ![]() |
![]() |
epithelial membrane protein 1 | |||||||
204924_AT | TLR2 | G | X | S | ![]() |
![]() |
toll-like receptor 2 | ||||||
205067_AT | IL1B | G | X | P | C | S | ![]() |
![]() |
interleukin 1, beta | ||||
39402_AT | IL1B | G | X | P | C | S | ![]() |
![]() |
interleukin 1, beta |